Author

K. Rahimi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 4 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A.-M. Mes-Masson· 4 shared D. Provencher· 3 shared F. Rodier· 3 shared M. Skulimowski· 3 shared E. Carmona· 2 shared I. Clement· 2 shared J. Lafontaine· 2 shared L. Portelance· 2 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A.-M. Mes-Masson

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A senescence-like state is beneficial for ovarian cancer treatment

M. Skulimowski, L. Calvo Gonzalez, S. Cheng, I. Clement, L. Portelance, Y. Zhan, E. Carmona, J. Lafontaine, M. Deladurantaye, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

This study shows that senescence in ovarian cancer cells after chemotherapy correlates with better patient survival, suggesting senescence could be a therapeutic target.

bioRxiv · Sep 30, 2023 · PreprintCancer Biology

53BP1 mediates sensitivity to chemotherapy and is associated with poor clinical outcomes in high-grade serous ovarian cancer

M. Skulimowski, J. Bourbonnais, N. Malaquin, H. Fleury, I. Clement, L. Communal, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

This study shows that high 53BP1 levels in ovarian cancer are linked to poor survival and chemotherapy resistance, suggesting it could be a therapeutic target.

bioRxiv · Sep 30, 2023 · PreprintCancer Biology

Predicting developmental relationships of tumor resident and circulating T cells in ovarian cancer

M. dos Santos Carneiro, Y. Bareche, C. Zhao, P. Thebault, K. Rahimi, D. Provenche, V. Samouelian, B. Cormier, J.-F. Cailhier, A.-M. Mes-Masson, S. Petropoulos, J. Stagg, R. Lapointe

The paper identifies developmental relationships between tumor and circulating T cells in ovarian cancer using single-cell transcriptomics and TCR analysis, revealing a differentiation pathway and interactions with Tfh-like cells.

bioRxiv · Feb 28, 2023 · PreprintImmunology

miR-216b-5p is Down-Regulated in Human Breast Cancer and Inhibits Proliferation and Progression by Targeting HDAC8 Oncogene

M.-N. Menbari, K. Rahimi, A. Ahmadi, S. Mohammadi-Yeganeh, A. Elyasi, N. Darvishi, V. Hosseini, M. Abdi

This study shows miR-216b-5p is down-regulated in breast cancer and inhibits proliferation by targeting HDAC8, with lower miR-216b-5p levels linked to lymph node metastasis and larger tumor size.

bioRxiv · Dec 19, 2018 · PreprintCancer Biology

Isolation of cancer stem cells by selection for miR-302 expressing cells

K. Rahimi, A. C. Fuchtbauer, F. Fathi, S. J. Mowla, E.-M. Fuchtbauer

This study isolates cancer stem cells by selecting for cells expressing miR-302, demonstrating that these cells can be propagated in culture and retain stem cell characteristics.

bioRxiv · Sep 26, 2018Cancer Biology

Cellular senescence is a central response to cytotoxic chemotherapy in high-grade serous ovarian cancer

L. Calvo, S. Cheng, M. Skulimowski, I. Clément, L. Portelance, Y. Zhan, E. Carmona, J. Lafontaine, M. de Ladurantaye, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

The paper shows that chemotherapy induces cellular senescence in high-grade serous ovarian cancer, which correlates with better patient survival.

bioRxiv · Sep 24, 2018 · PreprintCancer Biology